Dorothy

Hims & Hers has ceased offering a compounded weight-loss pill that mimicked Novo Nordisk’s FDA-approved drug Wegovy, following threats of legal action and new regulatory signals from the U.S. Food and Drug Administration (FDA). The FDA announced plans to restrict the use of GLP-1 ingredients—such as semaglutide—in non-approved compounded formulations, targeting companies like Hims & Hers that offer lower-cost alternatives to branded medications. This action comes amid growing scrutiny over the proliferation of unapproved versions of popular obesity treatments, which industry leaders argue undermine drug development and safety standards. While all sources agree on the core events—the FDA’s regulatory intent and Hims & Hers’ decision to discontinue the product—they differ in framing. CNBC emphasizes the company’s response to legal threats and the resulting drop in its stock price, highlighting market consequences. The Financial Times frames the episode as part of a broader U.S. government crackdown on “copycat” drugs, positioning Novo Nordisk as a victim of market undercutting. The FDA’s actions are presented by all as regulatory enforcement, but the Financial Times and CNBC imply a conflict between innovation and intellectual property, while the FDA’s position is framed as protecting public health and drug approval integrity.